Genetically Informed Prostate Cancer Treatment for Metastatic Disease

Urol Clin North Am. 2021 Aug;48(3):365-371. doi: 10.1016/j.ucl.2021.03.006. Epub 2021 Jun 10.ABSTRACTGermline testing should be performed to support treatment selection for patients with metastatic prostate cancer, and should be identified in patients with high-risk localized disease. Patients with germline BRCA1/2 mutations should be educated regarding additional personal cancer risk, and risk for family members. Guidelines recommend that all men with metastatic prostate cancer should also undergo somatic tissue and germline testing for priority genes BRCA1/2, PALB2, ATM, and MSH2/6. The advent of high throughput sequencing enables patients to be tested for a more comprehensive panel of germline and somatic mutations.PMID:34210491 | DOI:10.1016/j.ucl.2021.03.006

Source: The Urologic Clinics of North America - July 2, 2021 Category: Urology & Nephrology Authors: Aisha L Siebert Brittany M Szymaniak Yazan Numan Alicia K Morgans Source Type: research